Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGI-110 with cisplatin and gemcitabine in bladder cancer
ISRCTN16332228Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Apr 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of guadecitabine, cisplatin and gemcitabine in bladder cancer (6 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Recommended phase II dose. Started Apr 2016; status: completed.
02
Drugs
guadecitabinecisplatingemcitabine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on ISRCTN16332228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16332228.